Overall and sex-stratified paroxysmal tachycardia-related age-adjusted mortality rates per 100,000 in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

S1 Graphical abstract - by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000, stratified by census regions in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000 in adults in the metropolitan and non-metropolitan areas in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Supporting information – data for plots. by Maria Nadinskaia (22662419)

Subjects:

Morphometric analysis of histological slides in sarcopenia modeling by portal vein ligation and pyloric vein ligation. by Maria Nadinskaia (22662419)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000, stratified by race in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000, stratified by age groups in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Liver and spleen mass in sarcopenia-hyperammonemia modelling on Day 30. by Maria Nadinskaia (22662419)

Subjects:

Paroxysmal tachycardia-related deaths and age-adjusted mortality rates per 100,000, stratified by state in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

“…The Y-axis represents the fold change, while the X-axis indicates the significance of differential expression. …”

Sociodemographic characteristics. by Hea Ree Park (10769827)

Subjects:

Regression analysis of sleep habits and sleep-related symptoms associated with pandemic status. by Hea Ree Park (10769827)

Subjects:

Study flow chart. by Hea Ree Park (10769827)

Subjects:

Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

“…We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Changes in maximal strength within each group after treatment. by Sergio R. Thomaz (20308465)

Variation of the most appropriate p value significance threshold with different ratios of the standard deviations and sample sizes. by Farrokh Habibzadeh (12256529)

The rate of resistivity change under unsaturated conditions at different times. by Kui Suo (20614613)